Form 4: Aquestive Therapeutics CEO Sells Shares
Statement of Changes in Beneficial Ownership
Aquestive Therapeutics President and CEO Daniel Barber reported a sale of 25,000 shares of common stock.
Summary
- Daniel Barber, President and CEO of Aquestive Therapeutics, Inc., sold 25,000 shares of common stock on June 15, 2026.
- The sale was executed at a weighted average price of $4.1604 per share, with individual transactions ranging from $4.14 to $4.235.
- Following this transaction, Mr. Barber beneficially owns 635,574 shares of common stock.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a slightly negative sentiment due to the CEO selling a notable number of shares, which can be interpreted as a bearish signal by investors, despite the transaction being potentially for personal reasons.
Negatives
- The CEO sold a significant number of shares, which could be perceived negatively by the market.
Future Outlook
No specific future outlook or guidance is provided in this filing, as it is a statement of changes in beneficial ownership.
Industry Context
StockSavvy.ai notes that insider selling, particularly by a CEO, can sometimes signal a lack of confidence in future stock performance, although it can also be for personal financial planning reasons. The context of the broader market and company-specific news would be crucial for a complete assessment.
Stakeholder Impact
- Shareholders may view the CEO's sale of shares with concern, potentially leading to short-term negative pressure on the stock price.
- Employees with stock options or grants may be influenced by the CEO's selling activity.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of execution of Power of Attorney document. |
| 06/15/2026 | Date of earliest transaction reported in Form 4. |
| 06/17/2026 | Date of signature for the Form 4 filing. |
Recommendation
holdThe filing reports an insider sale by the CEO, which warrants attention. However, without further context on the reasons for the sale or the company's overall financial health and prospects, a 'hold' recommendation is prudent. Investors should seek additional information before making a definitive decision.
Keywords
Aquestive Therapeutics, AQST, Form 4, Insider Trading, Stock Sale, CEO, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.